Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...
Patients with high-risk treatment-refractory mantle cell lymphoma (MCL) show significant survival benefits with treatment with mosunetuzumab combined with polatuzumab vedotin (mosun-pola), new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback